Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomized, Double-Blind, Multicenter Trial of Amplimexon Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy Naïve Pancreatic Adenocarcinoma (Stage IV).

Next Previous
X
Search
Trial Profile

A Phase 2 Randomized, Double-Blind, Multicenter Trial of Amplimexon Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy Naïve Pancreatic Adenocarcinoma (Stage IV).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imexon (Primary) ; Gemcitabine
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AmpliMed

    • Most Recent Events

    • 10 Jul 2010 Disappointing results have been presented in an AmpliMed media release. Based on these results it is unlikely AmpliMed will continue onto phase III clinical trials with imexon in pancreatic cancer.
    • 10 Jul 2010 Status changed from active, no longer recruiting to completed.
    • 10 Jul 2010 Primary endpoint 'Overall survival' has not been met, according to an AmpliMed media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top